Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

被引：0
|
作者：
Mascarella, Marco Antonio
Olonisakin, Tolani
Rumde, Purva
Vendra, Varun
Nance, Melonie
Kim, Seungwon
Kubik, Mark
Sridharan, Shaum
Ferris, Robert
Fenton, Moon
Clayburgh, Daniel
Ohr, James
Sen, Malabika
Joyce, Sonali
Herman, James
Grandis, Jennifer
Zandberg, Dan
Duvvuri, Umamaheswar
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4338
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Total Neoadjuvant Therapy for Operable Pancreatic Cancer
    Kim, Rebecca Y.
    Christians, Kathleen K.
    Aldakkak, Mohammed
    Clarke, Callisia N.
    George, Ben
    Kamgar, Mandana
    Khan, Abdul H.
    Kulkarni, Naveen
    Hall, William A.
    Erickson, Beth A.
    Evans, Douglas B.
    Tsai, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2246 - 2256
  • [22] DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival
    Papalouka, Chara
    Adamaki, Maria
    Batsaki, Panagiota
    Zoumpourlis, Panagiotis
    Tsintarakis, Antonis
    Goulielmaki, Maria
    Fortis, Sotirios P.
    Baxevanis, Constantin N.
    Zoumpourlis, Vassilis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [23] Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
    Caroline J. Rieser
    Mazen Zenati
    Sowmya Narayanan
    Nathan Bahary
    Kenneth K. Lee
    Alessandro Paniccia
    David L. Bartlett
    Amer H. Zureikat
    Annals of Surgical Oncology, 2021, 28 : 6264 - 6272
  • [24] Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
    Rieser, Caroline J.
    Zenati, Mazen
    Narayanan, Sowmya
    Bahary, Nathan
    Lee, Kenneth K.
    Paniccia, Alessandro
    Bartlett, David L.
    Zureikat, Amer H.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (11) : 6264 - 6272
  • [25] Integration of molecular targeted therapy with radiation in head and neck cancer
    Du, Yu
    Peyser, Noah D.
    Grandis, Jennifer R.
    PHARMACOLOGY & THERAPEUTICS, 2014, 142 (01) : 88 - 98
  • [26] Survival Benefit from Cancer-Directed Surgery for Metastatic Head and Neck Cancer
    Zhu, Runqiu
    Zhu, Huiyong
    LARYNGOSCOPE, 2024, 134 (03): : 1288 - 1298
  • [27] Do the conventional clinicopathologic parameters predict for response and survival in head and neck cancer patients undergoing neoadjuvant chemotherapy?
    Fonseca, E
    Cruz, JJ
    Duenas, A
    Gomez, A
    Sanchez, P
    Martin, G
    Nieto, A
    Soria, P
    Munoz, A
    Gomez, JL
    Pardal, JL
    TUMORI JOURNAL, 1996, 82 (06): : 560 - 566
  • [28] Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma
    Franchin, G
    Vaccher, E
    Gobitti, C
    Minatel, E
    Politi, D
    Talamini, R
    Di Gennaro, G
    Savignano, G
    Trovò, MG
    Tirelli, U
    Barzan, L
    ORAL ONCOLOGY, 2005, 41 (05) : 526 - 533
  • [29] Neoadjuvant Capecitabine in Operable HPV-Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting
    Mascarella, Marco A.
    Richardson, Keith
    Mlynarek, Alex
    Hier, Michael P.
    Caglar, Derin
    Florianova, Livia
    Pusztaszeri, Marc Philippe
    Sultanem, Khalil
    Sadeghi, Nader
    Bouganim, Nathaniel
    Esfahani, Khashayar
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 171 (06) : 1773 - 1779
  • [30] The functional GRHL3-FLG axis predicts targeted therapy response in head and neck cancer
    Bai, Y.
    Zhao, Z.
    Denderen, B. J. V.
    Darido, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S17 - S17
12345